Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP. Maguire MF, et al. Among authors: parkin n. J Virol. 2002 Aug;76(15):7398-406. doi: 10.1128/jvi.76.15.7398-7406.2002. J Virol. 2002. PMID: 12097552 Free PMC article.
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z, Paxinos EE, Averbuch D, Maayan S, Parkin NT, Engelhard D, Lorber M, Istomin V, Shaked Y, Mendelson E, Ram D, Petropoulos CJ, Schapiro JM. Grossman Z, et al. Antimicrob Agents Chemother. 2004 Jun;48(6):2159-65. doi: 10.1128/AAC.48.6.2159-2165.2004. Antimicrob Agents Chemother. 2004. PMID: 15155216 Free PMC article. Clinical Trial.
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. Resch W, et al. Among authors: parkin n. J Virol. 2002 Sep;76(17):8659-66. doi: 10.1128/jvi.76.17.8659-8666.2002. J Virol. 2002. PMID: 12163585 Free PMC article.
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.
Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM. Petropoulos CJ, et al. Among authors: parkin nt. Antimicrob Agents Chemother. 2000 Apr;44(4):920-8. doi: 10.1128/AAC.44.4.920-928.2000. Antimicrob Agents Chemother. 2000. PMID: 10722492 Free PMC article.
161 results